Market by Therapeutics & Diagnostics and Geography | Forecast 2019-2027
The global Alzheimer’s disease therapeutics and diagnostics market is projected to exhibit an upward trend by progressing at a CAGR of 7.78% throughout the estimated period of 2019 to 2027.
Alzheimer's disease is a type of dementia that causes problems like memory degradation, along with behavioral and thinking changes. The disease develops slowly and worsens as time progresses. Recently, Alzheimer’s was found to be the sixth leading cause of death in the United States. People with Alzheimer's, on an average, live for eight years after their symptoms become visible, but this can range from four to twenty years, depending on the individual’s age and other health conditions.
As per the Alzheimer’s Association data for the year 2016, an estimated 5.4 million Americans of all ages have been diagnosed with Alzheimer's disease. One in nine individuals aged 65 and above has been diagnosed with Alzheimer's. As per the Alzheimer’s Disease International data for 2015, there are an estimated 46.8 million individuals worldwide living with dementia and this trend is further expected to grow in future due to the rising aging population across the world, thanks to the improved life expectancy. Hence, there is an increasing demand for Alzheimer’s therapeutics and diagnostics globally.
Recent developments in research have enhanced the understanding and diagnosis of neurological disorders. The rise in the utilization of techniques such as biomarkers and positron emission tomography has facilitated the radiologists to analyze the amyloid plaques that are specific to Alzheimer’s patients. These developments have enabled researchers to eradicate "trial and error" prescription, ushering the development of personalized medicine for Alzheimer’s. Also, the surge in funding for the advancement of personalized medicines has aided in promoting the growth of therapeutics being adopted in Alzheimer’s disease. Also, investments in personalized medicines in the US have grown by over xx% during 2012-2016.
The various components studied within the global Alzheimer’s disease therapeutics market report are Porter’s five force model, etymology, parent market outlook, strategic buying criteria outlook, investments outlook, key findings, industry structure, regulatory framework and agency. Also, etiology and pipeline outlook, phases and sternness of disease have been studied in the report.
Factors such as the growing prevalence of Alzheimer’s disease, increasing geriatric population and the substantial increase in the investments made by governments are the top factors contributing to the growth of the market globally. However, restraints like strict government regulations and the increased expenses for the treatments are responsible for obstructing the market growth globally. Opportunities like in-vitro diagnostics techniques and rising investments in the R&D of personalized medicines are leveraging the market to proliferate towards the projected growth over the coming years. However, low awareness about new therapies and very few professionals available for the treatment are the major challenges faced by the market.
The major regions covered in the global Alzheimer’s disease therapeutics and diagnostics market are:
• North America: United States and Canada
• Europe: United Kingdom, Germany, France, Spain, Italy, Russia and Rest of Europe
• Asia-Pacific: China, Japan, India, Australia & New Zealand, South Korea, ASEAN countries and Rest of Asia-Pacific
• Latin America: Brazil, Mexico and Rest of Latin America
• The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East and Africa
The global Alzheimer’s disease therapeutics and diagnostics market is segmented as follows:
• Therapeutics and Diagnostics:
O Therapeutics
• Drugs - Market Drugs and Pipeline Drugs
• Disease Stage - Late Stage: Severe AD and Early/Middle Stage: Mild to Moderate AD
• Prodromal Stage
• Generic and Branded
O Diagnostics
• Lumbar Puncture Test
• Positron Emission Tomography
• Electroencephalography
• Magnetic Resonance Imaging
• Computed Tomography
• Other Diagnostics
The major players operating in the global Alzheimer’s disease therapeutics and diagnostics market include GE Healthcare, Merck and Co., Baxter, Biogen, DiaGenic ASA, Cognoptix, Roche, AXON Neuroscience SE, Sun Pharmaceutical Industries Ltd., AbbVie, Siemens Healthineers AG, Amarantus BioScience Holdings Inc., Piramal Enterprises Ltd., and Johnson & Johnson.
The strategic analysis for each of these companies in the global Alzheimer’s disease therapeutics and diagnostics market has been covered in this report. The market share of the company guides with information about the top players and their presence in the market has been provided.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCE MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREATS
OF SUBSTITUTE PRODUCT
2.2.3. BARGAINING
POWER OF BUYER
2.2.4. BARGAINING
POWER OF SUPPLIER
2.2.5. INTENSITY
OF COMPETITIVE RIVALRY
2.3. VENDOR
SCORECARD
2.4. ETYMOLOGY
2.5. PARENT
MARKET OUTLOOK
2.6. STRATEGIC
BUYING CRITERIA OUTLOOK
2.7. INVESTMENTS
OUTLOOK
2.8. KEY
FINDINGS
2.9. INDUSTRY
STRUCTURE
2.9.1. RESEARCH
AND DEVELOPMENT
2.9.2. MANUFACTURING
2.9.3. RAW
MATERIALS
2.9.4. END
USER
2.9.5. WHOLESALERS
2.10. REGULATORY
FRAMEWORK
2.11. THE
UNITED STATES AND EUROPE REGULATORY AGENCY
2.12. ALZHEIMER'S
DISEASE ETIOLOGY
2.13. PIPELINE
OUTLOOK
2.14. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.15. MARKET
DRIVERS
2.15.1. GROWTH
OF THE ALZHEIMER’S DISEASE
2.15.2. GROWING
GERIATRIC POPULATION
2.15.3. SUBSTANTIAL
INVESTMENTS BY GOVERNMENT IN RESEARCH
2.16. MARKET
RESTRAINTS
2.16.1. STRINGENT
GOVERNMENT REGULATIONS
2.16.2. THE
TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH
2.17. MARKET
OPPORTUNITIES
2.17.1. IN-VITRO
DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET
2.17.2. R&D
INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING
2.18. MARKET
CHALLENGES
2.18.1. AWARENESS
IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE
2.18.2. VERY
FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE
3. ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND
DIAGNOSTICS
3.1. THERAPEUTICS
3.1.1. THERAPEUTICS
BY DRUGS
3.1.1.1. MARKETED
DRUGS
3.1.1.2. PIPELINE
DRUGS
3.1.2. THERAPEUTICS
BY DISEASE STAGE
3.1.2.1. LATE
STAGE: SEVERE AD
3.1.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.1.3. PRODROMAL
STAGE
3.1.4. THERAPEUTICS
BY GENERIC AND BRANDED
3.1.4.1. BRANDED
3.1.4.2. GENERIC
3.2. DIAGNOSTIC
TYPE
3.2.1. LUMBAR
PUNCTURE TEST
3.2.2. POSITRON
EMISSION TOMOGRAPHY
3.2.3. ELECTROENCEPHALOGRAPHY
3.2.4. MAGNETIC
RESONANCE IMAGING
3.2.5. COMPUTED
TOMOGRAPHY
3.2.6. OTHER
DIAGNOSTICS
4. ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK
4.1. NORTH
AMERICA
4.1.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.1.2. COUNTRY
ANALYSIS
4.1.2.1. THE
UNITED STATES
4.1.2.2. CANADA
4.2. EUROPE
4.2.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.2.2. COUNTRY
ANALYSIS
4.2.2.1. THE
UNITED KINGDOM
4.2.2.2. FRANCE
4.2.2.3. GERMANY
4.2.2.4. SPAIN
4.2.2.5. ITALY
4.2.2.6. RUSSIA
4.2.2.7. REST
OF EUROPE
4.3. ASIA-PACIFIC
4.3.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.3.2. COUNTRY
ANALYSIS
4.3.2.1. CHINA
4.3.2.2. INDIA
4.3.2.3. JAPAN
4.3.2.4. AUSTRALIA
AND NEW ZEALAND
4.3.2.5. SOUTH
KOREA
4.3.2.6. ASEAN
COUNTRIES
4.3.2.7. REST
OF ASIA-PACIFIC
4.4. LATIN
AMERICA
4.4.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.4.2. COUNTRY
ANALYSIS
4.4.2.1. BRAZIL
4.4.2.2. MEXICO
4.4.2.3. REST
OF LATIN AMERICA
4.5. MIDDLE
EAST AND AFRICA
4.5.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.5.2. COUNTRY
ANALYSIS
4.5.2.1. SAUDI
ARABIA
4.5.2.2. TURKEY
4.5.2.3. UNITED
ARAB EMIRATES
4.5.2.4. SOUTH
AFRICA
4.5.2.5. REST
OF MIDDLE EAST & AFRICA
5. COMPANY
PROFILES
5.1. ABBVIE
5.2. AMARANTUS
BIOSCIENCE HOLDINGS, INC.
5.3. AXON
NEUROSCIENCE SE
5.4. BAXTER
5.5. BIOGEN
5.6. COGNOPTIX
5.7. DIAGENIC
ASA
5.8. ROCHE
5.9. GE
HEALTHCARE
5.10. MERCK
5.11. JOHNSON
& JOHNSON
5.12. PIRAMAL
ENTERPRISES LTD.
5.13. SIEMENS
HEALTHINEERS AG
5.14. SUN
PHARMACEUTICAL INDUSTRIES LTD.
6. RESEARCH
METHODOLOGY & SCOPE
6.1. RESEARCH
SCOPE & DELIVERABLES
6.1.1. OBJECTIVES
OF STUDY
6.1.2. SCOPE
OF STUDY
6.2. SOURCES
OF DATA
6.2.1. PRIMARY
DATA SOURCES
6.2.2. SECONDARY
DATA SOURCES
6.3. RESEARCH
METHODOLOGY
6.3.1. EVALUATION
OF PROPOSED MARKET
6.3.2. IDENTIFICATION
OF DATA SOURCES
6.3.3. ASSESSMENT
OF MARKET DETERMINANTS
6.3.4. DATA
COLLECTION
6.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 2 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 3 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($ MILLION)
TABLE 4 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($ MILLION)
TABLE 5 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 ($
MILLION)
TABLE 6 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)
TABLE 7 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027
($ MILLION)
TABLE 9 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 10 EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND
DIAGNOSTIC MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)
TABLE 11 EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND
DIAGNOSTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 12 ASIA-PACIFIC ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027
($ MILLION)
TABLE 13 ASIA-PACIFIC ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 14 LATIN AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027
($ MILLION)
TABLE 15 LATIN AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027
($ MILLION)
TABLE 17 MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE 1 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 2 INVESTMENTS IN ALZHEIMER’S DISEASE
TREATMENT
FIGURE 3 ALZHEIMER'S DRUGS IN THE PIPELINE BY
TREATMENT FOCUS (NUMBER OF DRUGS)
FIGURE 4 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)
FIGURE 5 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)
FIGURE 6 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN BRANDED 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN GENERIC 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET
IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)
FIGURE 19 THE UNITED STATES ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 20 CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 21 EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND
DIAGNOSTIC MARKET 2019-2027 ($ MILLION)
FIGURE 22 THE UNITED KINGDOM ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 23 FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 24 GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 25 SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 26 ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 27 RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 28 REST OF EUROPE ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 29 ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 30 CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 31 INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 32 JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 33 AUSTRALIA AND NEW ZEALAND ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 34 SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 35 ASEAN COUNTRIES ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 36 REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 37 LATIN AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 38 BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 39 MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 40 REST OF LATIN AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 42 SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 43 TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 44 UNITED ARAB EMIRATES ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 45 SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST OF MIDDLE EAST & AFRICA ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)